Chen Yi, Wang Xiao-Lin, Yan Zhi-Ping, Cheng Jie-Min, Wang Jian-Hua, Gong Gao-Quan, Qian Sheng, Luo Jian-Jun, Liu Qing-Xin
Department of Radiology, Affiliated Zhongshan Hospital, Medical Center of Fudan University, Shanghai 200032, China.
World J Gastroenterol. 2004 Dec 1;10(23):3506-10. doi: 10.3748/wjg.v10.i23.3506.
To determine the feasibility and safety of intraluminal brachytherapy in treatment of malignant obstructive jaundice (MOJ) and to evaluate the clinical effect of intraluminal brachytherapy on stent patency and patient survival.
Thirty-four patients with MOJ were included in this study. Having biliary stent placed, all patients were classified into intraluminal brachytherapy group (group A, n = 14) and control group (group B, n = 20) according to their own choice. Intraluminal brachytherapy regimen included: HDR-192Ir was used in the therapy, fractional doses of 4-7 Gy were given every 3-6 d for 3-4 times, and standard points were established at 0.5-1.0 cm. Some patients of both groups received transcatheter arterial chemoembolization (TACE) after stent placement.
In group A, the success rate of intraluminal brachytherapy was 98.0%, RTOG grade 1 acute radiation morbidity occurred in 3 patients, RTOG/EORTC grade 1 late radiation morbidity occurred in 1 patient. Mean stent patency of group A (12.6 mo) was significantly longer than that of group B (8.3 mo) (P<0.05). There was no significant difference in the mean survival (9.4 mo vs 6.0 mo) between the two groups.
HDR-192Ir intraluminal brachytherapy is a safe palliative therapy in treating MOJ, and it may prolong stent patency and has the potentiality of extending survival of patients with MOJ.
探讨腔内近距离放射治疗恶性梗阻性黄疸(MOJ)的可行性和安全性,并评估腔内近距离放射治疗对支架通畅性和患者生存的临床效果。
本研究纳入34例MOJ患者。所有患者均放置胆管支架,根据自身选择分为腔内近距离放射治疗组(A组,n = 14)和对照组(B组,n = 20)。腔内近距离放射治疗方案包括:采用高剂量率192铱进行治疗,每3 - 6天给予4 - 7 Gy的分次剂量,共3 - 4次,在0.5 - 1.0 cm处设定标准点。两组部分患者在支架置入后接受经动脉化疗栓塞术(TACE)。
A组腔内近距离放射治疗成功率为98.0%,3例患者发生RTOG 1级急性放射性损伤,1例患者发生RTOG/EORTC 1级晚期放射性损伤。A组支架平均通畅时间(12.6个月)显著长于B组(8.3个月)(P<0.05)。两组平均生存期无显著差异(9.4个月对6.个月)。
高剂量率192铱腔内近距离放射治疗是治疗MOJ的一种安全的姑息治疗方法,可能延长支架通畅时间,并有延长MOJ患者生存期的潜力。